Swedish Orphan Biovitrum Stock Net Asset
| SOBI Stock | SEK 307.80 6.60 2.19% |
Swedish Orphan Biovitrum fundamentals help investors to digest information that contributes to Swedish Orphan's financial success or failures. It also enables traders to predict the movement of Swedish Stock. The fundamental analysis module provides a way to measure Swedish Orphan's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Swedish Orphan stock.
Swedish |
Swedish Orphan Biovitrum Company Net Asset Analysis
Swedish Orphan's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Swedish Orphan Net Asset | 48.66 B |
Most of Swedish Orphan's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Swedish Orphan Biovitrum is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Swedish Orphan Biovitrum has a Net Asset of 48.66 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers - Specialty & Generic industry. The net asset for all Sweden stocks is notably lower than that of the firm.
Swedish Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Swedish Orphan's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Swedish Orphan could also be used in its relative valuation, which is a method of valuing Swedish Orphan by comparing valuation metrics of similar companies.Swedish Orphan is currently under evaluation in net asset category among its peers.
Swedish Fundamentals
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.24 % | |||
| Current Valuation | 72.79 B | |||
| Shares Outstanding | 295.99 M | |||
| Shares Owned By Insiders | 4.00 % | |||
| Shares Owned By Institutions | 70.55 % | |||
| Price To Earning | 20.29 X | |||
| Price To Book | 2.51 X | |||
| Price To Sales | 3.67 X | |||
| Revenue | 15.53 B | |||
| Gross Profit | 14.38 B | |||
| EBITDA | 5.72 B | |||
| Net Income | 2.68 B | |||
| Cash And Equivalents | 1.04 B | |||
| Cash Per Share | 4.04 X | |||
| Total Debt | 9.02 B | |||
| Debt To Equity | 39.80 % | |||
| Current Ratio | 0.75 X | |||
| Book Value Per Share | 89.61 X | |||
| Cash Flow From Operations | 5.47 B | |||
| Earnings Per Share | 10.10 X | |||
| Price To Earnings To Growth | 1.98 X | |||
| Target Price | 269.56 | |||
| Number Of Employees | 1.56 K | |||
| Beta | 0.39 | |||
| Market Capitalization | 73.08 B | |||
| Total Asset | 48.66 B | |||
| Working Capital | 1.42 B | |||
| Current Asset | 2.68 B | |||
| Current Liabilities | 1.26 B | |||
| Z Score | 4.8 | |||
| Net Asset | 48.66 B |
About Swedish Orphan Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Swedish Orphan Biovitrum's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Swedish Orphan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Swedish Orphan Biovitrum based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Swedish Stock Analysis
When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.